Prelude Therapeutics (PRLD) Operating Expenses (2019 - 2026)

Prelude Therapeutics has disclosed Operating Expenses across 8 years of filings, most recently posting $18.8 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $18.8 million, down 45.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $100.9 million (down 31.38% YoY), and the FY2025 annual result was $116.7 million, down 20.45% from the prior year.
• Operating Expenses came in at $18.8 million for Q1 2026 at Prelude Therapeutics, down from $23.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $37.8 million in Q4 2024 to a low of $18.8 million in Q1 2026.
• The 5-year median for Operating Expenses is $32.4 million (2023), against an average of $31.6 million.
• Across the five-year window, Operating Expenses soared 37.88% in 2022 and plunged 45.8% in 2026, its largest moves.
• Prelude Therapeutics' Operating Expenses stood at $33.4 million in 2022, then rose by 11.96% to $37.4 million in 2023, then climbed by 1.21% to $37.8 million in 2024, then tumbled by 39.24% to $23.0 million in 2025, then fell by 18.41% to $18.8 million in 2026.
• The last three Operating Expenses figures came in at $18.8 million (Q1 2026), $23.0 million (Q4 2025), and $26.9 million (Q3 2025), per Business Quant data.